Mindblown: a blog about philosophy.

(Reuters) -Real estate investment trust Boston Properties (NYSE:BXP) on Tuesday agreed to sell a 45% interest in two Massachusetts-based life sciences development properties to Norges Bank Investment Management at a gross valuation of about $1.66 billion. Shares of the REIT rose 9.4% in early trading and were on track for their best day in more […]

(Reuters) -Real estate investment trust Boston Properties (NYSE:BXP) on Tuesday agreed to sell a 45% interest in two Massachusetts-based life sciences development properties to Norges Bank Investment Management at a gross valuation of about $1.66 billion. Massachusetts, especially Cambridge and Boston, is known to be a hotspot for biotech companies including Moderna (NASDAQ:MRNA). The state […]

(Reuters) -Real estate investment trust Boston Properties (NYSE:BXP) on Tuesday agreed to sell a 45% interest in two Massachusetts-based life sciences development properties to Norges Bank Investment Management at a gross valuation of about $1.66 billion. Massachusetts, especially Cambridge and Boston, is known to be a hotspot for biotech companies including Moderna (NASDAQ:MRNA). The state […]

(Reuters) -Real estate investment trust Boston Properties (NYSE:BXP) on Tuesday agreed to sell a 45% interest in two Massachusetts-based life sciences development properties to Norges Bank Investment Management at a gross valuation of about $1.66 billion. Massachusetts, especially Cambridge and Boston, is known to be a hotspot for biotech companies including Moderna (NASDAQ:MRNA). The state […]

(Reuters) -Real estate investment trust Boston Properties (NYSE:BXP) on Tuesday agreed to sell a 45% interest in two Massachusetts-based life sciences development properties to Norges Bank Investment Management at a gross valuation of about $1.66 billion. Massachusetts, especially Cambridge and Boston, is known to be a hotspot for biotech companies including Moderna (NASDAQ:MRNA). The state […]

Telomir Pharmaceuticals (TELO) has filed for a proposed IPO. The company describes itself as: “We are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Based on our pre-clinical studies and if approved […]

Telomir Pharmaceuticals (TELO) has filed for a proposed IPO. The company describes itself as: “We are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Based on our pre-clinical studies and if approved […]

Telomir Pharmaceuticals (TELO) has filed for a proposed IPO. The company describes itself as: “We are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Based on our pre-clinical studies and if approved […]

Investing.com – Camtek (NASDAQ: CAMT) reported third quarter EPS of $0.48, in line with the analyst estimate of $0.48. Revenue for the quarter came in at $80.5M versus the consensus estimate of $78.2M. Camtek’s stock price closed at $65.20. It is up 46.09% in the last 3 months and up 153.70% in the last 12 […]

Investing.com – Camtek (NASDAQ: CAMT) reported third quarter EPS of $0.48, in line with the analyst estimate of $0.48. Revenue for the quarter came in at $80.5M versus the consensus estimate of $78.2M. Camtek’s stock price closed at $65.20. It is up 46.09% in the last 3 months and up 153.70% in the last 12 […]